JP2024533423A - 薬学的組成物およびその使用 - Google Patents

薬学的組成物およびその使用 Download PDF

Info

Publication number
JP2024533423A
JP2024533423A JP2024515562A JP2024515562A JP2024533423A JP 2024533423 A JP2024533423 A JP 2024533423A JP 2024515562 A JP2024515562 A JP 2024515562A JP 2024515562 A JP2024515562 A JP 2024515562A JP 2024533423 A JP2024533423 A JP 2024533423A
Authority
JP
Japan
Prior art keywords
flumonertinib
pharma
acceptable salt
egfr
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024515562A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024533423A5 (https=
Inventor
フイビン ルオ，
チン リー，
Original Assignee
シャンハイ アリスト ファーマシューティカルズ カンパニー， リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by シャンハイ アリスト ファーマシューティカルズ カンパニー， リミテッド filed Critical シャンハイ アリスト ファーマシューティカルズ カンパニー， リミテッド
Publication of JP2024533423A publication Critical patent/JP2024533423A/ja
Publication of JP2024533423A5 publication Critical patent/JP2024533423A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2024515562A 2021-09-10 2022-04-11 薬学的組成物およびその使用 Pending JP2024533423A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
PCT/CN2021/117692 WO2023035223A1 (zh) 2021-09-10 2021-09-10 药物组合物及其用途
CNPCT/CN2021/117692 2021-09-10
PCT/CN2022/086053 WO2023035611A1 (en) 2021-09-10 2022-04-11 Pharmaceutical composition and use thereof

Publications (2)

Publication Number Publication Date
JP2024533423A true JP2024533423A (ja) 2024-09-12
JP2024533423A5 JP2024533423A5 (https=) 2025-04-18

Family

ID=85507161

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024515562A Pending JP2024533423A (ja) 2021-09-10 2022-04-11 薬学的組成物およびその使用

Country Status (10)

Country Link
US (1) US20240366600A1 (https=)
EP (1) EP4398909A4 (https=)
JP (1) JP2024533423A (https=)
KR (1) KR20240074779A (https=)
CN (1) CN117957000A (https=)
AU (1) AU2022341942A1 (https=)
CA (1) CA3231192A1 (https=)
IL (1) IL311331A (https=)
MX (1) MX2024002822A (https=)
WO (2) WO2023035223A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116159062A (zh) * 2021-11-24 2023-05-26 上海艾力斯医药科技股份有限公司 药物组合物及其用途
JP2025510910A (ja) * 2022-03-31 2025-04-15 アストラゼネカ・アクチエボラーグ 癌の処置のための、ａｋｔ阻害剤との組み合わせにおける上皮成長因子受容体（ｅｇｆｒ）チロシンキナーゼ阻害剤
WO2024059962A1 (en) * 2022-09-19 2024-03-28 Shanghai Allist Pharmaceuticals Co., Ltd. Pharmaceutical composition and use thereof
CN116478138A (zh) * 2023-04-21 2023-07-25 江苏艾力斯生物医药有限公司 一种甲磺酸伏美替尼原料药的结晶方法
CN116893086A (zh) * 2023-04-28 2023-10-17 江苏艾力斯生物医药有限公司 一种靶向药甲磺酸伏美替尼片的模拟片及其制备方法
CN117547536A (zh) * 2023-11-15 2024-02-13 江苏艾力斯生物医药有限公司 一种药物组合物、其制备方法及应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017525685A (ja) * 2014-07-29 2017-09-07 上海艾力斯医薬科技有限公司 ピリジニルアミノピリミジン誘導体、その製造方法、および用途
JP2019507787A (ja) * 2016-03-07 2019-03-22 上海艾力斯医薬科技有限公司 ピリジニルアミノピリミジン誘導体の塩、その製造方法及びその使用

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110590749B (zh) * 2016-03-07 2020-11-06 上海艾力斯医药科技股份有限公司 吡啶胺基嘧啶衍生物甲磺酸盐的结晶形式及其制备和应用

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017525685A (ja) * 2014-07-29 2017-09-07 上海艾力斯医薬科技有限公司 ピリジニルアミノピリミジン誘導体、その製造方法、および用途
JP2019507787A (ja) * 2016-03-07 2019-03-22 上海艾力斯医薬科技有限公司 ピリジニルアミノピリミジン誘導体の塩、その製造方法及びその使用

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
"Study of FURMONERTINIB in Patients With NSCLC Having Exon 20 Insertion Mutation (FAVOUR)", CLINICALTRIALS, JPN6026014054, 25 August 2021 (2021-08-25), ISSN: 0005836448 *
GONZALVEZ, F. ET AL.: "Mobocertinib (TAK-788): A Targeted Inhibitor of EGFR Exon 20 Insertion Mutants in Non-Small Cell Lun", CANCER DISCOVERY, vol. 11, no. 7, JPN6026014060, 1 July 2021 (2021-07-01), pages 1672 - 1687, ISSN: 0005836450 *
HUANG, L. ET AL.: "Tyrosine kinase inhibitors for solid tumors in the past 20 years (2001-2020)", JOURNAL OF HEMATOLOGY & ONCOLOGY, vol. 13, no. 1, JPN6026014056, 2020, pages 1 - 23, ISSN: 0005836451 *
MENG, J. ET AL.: "Metabolic disposition of the EGFR covalent inhibitor furmonertinib in humans", ACTA PHARMACOLOGICA SINICA, vol. 43, no. 2, JPN6026014055, 29 April 2021 (2021-04-29), pages 494 - 503, ISSN: 0005836449 *
REMON, J. ET AL.: "EGFR exon 20 insertions in advanced non-small cell lung cancer: A new history begins", CANCER TREATMENT REVIEWS, vol. 90, JPN6026014057, 2020, pages 1 - 10, ISSN: 0005836452 *
SHI, Y. ET AL.: "Safety, Clinical Activity, and Pharmacokinetics of Alflutinib (AST2818) in Patients With Advanced NS", JOURNAL OF THORACIC ONCOLOGY, vol. 15, no. 6, JPN6026014058, 2020, pages 1015 - 1026, ISSN: 0005836453 *
VASCONCELOS, P. E. N. S. ET AL.: "EGFR-A763_Y764insFQEA Is a Unique Exon 20 Insertion Mutation That Displays Sensitivity to Approved a", JTO CLINICAL AND RESEARCH REPORTS, vol. 1, no. 3, JPN6026014059, 2020, pages 1 - 8, ISSN: 0005836454 *

Also Published As

Publication number Publication date
CN117957000A (zh) 2024-04-30
KR20240074779A (ko) 2024-05-28
AU2022341942A1 (en) 2024-05-02
EP4398909A1 (en) 2024-07-17
CA3231192A1 (en) 2023-03-16
IL311331A (en) 2024-05-01
EP4398909A4 (en) 2025-08-13
WO2023035223A1 (zh) 2023-03-16
WO2023035611A1 (en) 2023-03-16
US20240366600A1 (en) 2024-11-07
MX2024002822A (es) 2024-05-03

Similar Documents

Publication Publication Date Title
JP2024533423A (ja) 薬学的組成物およびその使用
JP7611855B2 (ja) ユーイング肉腫治療用キノリン系化合物又はその薬学的に許容される塩
US20180353602A1 (en) Combination of hdac inhibitor and anti-pd-l1 antibody for treatment of cancer
US11419862B2 (en) Quinoline derivative for treatment of nasopharyngeal carcinoma
CN112043702A (zh) 用于联合治疗结直肠癌的喹啉类化合物
US20200171061A1 (en) Methods for Cancer Therapy
CN113811298B (zh) 用于联合治疗小细胞肺癌的喹啉衍生物
WO2023093663A1 (en) Pharmaceutical composition and use thereof
CN112043831A (zh) 用于联合治疗乳腺癌的喹啉类化合物
WO2024061203A1 (en) Pharmaceutical composition and use thereof
JP7571053B2 (ja) 軟部肉腫の併用療法用キノリン誘導体
HK40110967A (zh) 药物组合物及其用途
CN113750096A (zh) 用于治疗外周t细胞淋巴瘤的喹啉衍生物
HK40116696A (zh) 药物组合物及其用途
CN112294814A (zh) 用于治疗胶质母细胞瘤的喹啉衍生物
HK40065487A (en) Quinoline derivative used for soft tissue sarcoma combination therapy
HK40072142A (en) Quinoline derivative used for combination treatment of small cell lung cancer

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250410

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250410

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20260306

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260408